We can’t show the full text here under this license.
Abstract
Metabolic dysfunction-associated steatotic liver disease () is linked to diabetes and is often exacerbated by hyperglycemia.
- MASLD is associated with obesity and insulin resistance.
- There is a bidirectional relationship where MASLD contributes to insulin resistance and hyperglycemia accelerates MASLD's progression to metabolic dysfunction-associated steatohepatitis ().
- Hepatokines, influenced by overnutrition and hyperglycemia, play a role in the connection between liver fat accumulation and insulin resistance in muscle.
- In diabetic individuals, hyperglycemia and free fatty acids promote fat production and increase energy use in the liver, which could lead to oxidative stress and inflammation.
- Damage to liver endothelial cells has been observed in diabetic conditions, as indicated by transcriptome analyses of MASH.
- Effective treatments for MASH include certain antidiabetic medications, with pioglitazone and GLP-1 receptor agonists recommended for glycemic control in type 2 diabetes patients.
Simplified